Advertisement
Screener

PROFOUND MEDICAL CORP. (PROF) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price

2.8 / 5 stars · 68/120 Roast Me

PROFOUND MEDICAL CORP. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price

PROFOUND MEDICAL CORP. (PROF) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of 15.69 CAD/shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-08-06

  • PROFOUND MEDICAL CORP. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2026-03-31 was 11.86 CAD/shares, a 34.62% decline year-over-year.
  • PROFOUND MEDICAL CORP. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2025-03-31 was 18.14 CAD/shares.
  • PROFOUND MEDICAL CORP. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2025 was 16.60 CAD/shares, a 2.66% increase from fiscal 2024.
  • PROFOUND MEDICAL CORP. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2024 was 16.17 CAD/shares, a 0.25% increase from fiscal 2023.
  • PROFOUND MEDICAL CORP. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2023 was 16.13 CAD/shares.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month
2026-06-3015.69 CAD/shares
10-Q · filed 2026-08-06
2026-03-3111.86 CAD/shares
10-Q · filed 2026-05-07
2025-12-3116.60 CAD/shares
10-K · filed 2026-03-05
2025-09-3016.82 CAD/shares
10-Q · filed 2025-11-13
2025-06-3017.77 CAD/shares
10-Q · filed 2025-08-14
2025-03-3118.14 CAD/shares
10-Q · filed 2025-05-08
2024-12-3116.17 CAD/shares
10-K · filed 2026-03-05
2023-12-3116.13 CAD/shares
10-K · filed 2025-03-07

Similar stocks

Stock NameCountryMarket CapPE Ratio
Neuronetics, Inc. (STIM)United States$0.216B-3.25
PRO DEX INC (PDEX)United States$0.234B13.64
UTAH MEDICAL PRODUCTS INC (UTMD)United States$0.238B20.93
Lucid Diagnostics Inc. (LUCD)United States$0.170B
InfuSystem Holdings, Inc (INFU)United States$0.253B22.52
KORU Medical Systems, Inc. (KRMD)United States$0.151B-106.78
Anika Therapeutics, Inc. (ANIK)United States$0.272B-51.71
ORASURE TECHNOLOGIES INC (OSUR)United States$0.272B-6.26
Cytosorbents Corp (CTSO)United States$0.274B-1.29
TriSalus Life Sciences, Inc. (TLSI)United States$0.283B-9.92